Value-based pricing for pharmaceuticals : its role, specification and prospects in a newly devolved NHS

摘要: In December 2010, the Government launched its consultation on plans to change way medicines are priced in UK. By 2014, a system of ‘value-based pricing’ (VBP) will replace current Pharmaceutical Price Regulation Scheme (PPRS), which is voluntary agreement between Department Health (DH) and pharmaceutical industry whereby companies negotiate profit rates from drug sales National Service (NHS) every 5 years utilising price controls. The concept VBP emerged Office Fair Trading (OFT) report 2007, recommended that prices individual products should reflect their 'clinical therapeutic value patients broader NHS'. introduction provides an opportunity found pricing access new health technologies sound principles; reflective social values reality budget constrained NHS. This requires: clarity key issues principle value; as well critical details how it be implemented operate. Research Report describes potential framework for type devolved NHS envisioned recent government reforms. It also considers some features arrangements need appropriately specified if benefits realised.